Skip to main content
. Author manuscript; available in PMC: 2020 Aug 2.
Published in final edited form as: Clin Cancer Res. 2018 Mar 13;24(12):2820–2827. doi: 10.1158/1078-0432.CCR-17-2940

Figure 3. Epicolon I. Overall Survival Stage IV CRC Patients. TFAP2E Methylation.

Figure 3.

(A) Overall survival of patients with stage IV disease during FU (follow-up), according to TFAP2E methylation status. (B) Overall survival of patients that received or did not receive (C) chemotherapy according to TFAP2E methylation status. (D) Overall survival of patients with stage IV disease and TFAP2E methylated tumors and (E) TFAP2E non-methylated tumors